These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1160 related articles for article (PubMed ID: 34388396)
1. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396 [TBL] [Abstract][Full Text] [Related]
2. Teclistamab in Relapsed or Refractory Multiple Myeloma. Moreau P; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Nooka AK; Martin T; Rosinol L; Chari A; Karlin L; Benboubker L; Mateos MV; Bahlis N; Popat R; Besemer B; Martínez-López J; Sidana S; Delforge M; Pei L; Trancucci D; Verona R; Girgis S; Lin SXW; Olyslager Y; Jaffe M; Uhlar C; Stephenson T; Van Rampelbergh R; Banerjee A; Goldberg JD; Kobos R; Krishnan A; Usmani SZ N Engl J Med; 2022 Aug; 387(6):495-505. PubMed ID: 35661166 [TBL] [Abstract][Full Text] [Related]
3. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study. Nooka AK; Rodriguez C; Mateos MV; Manier S; Chastain K; Banerjee A; Kobos R; Qi K; Verona R; Doyle M; Martin TG; van de Donk NWCJ Cancer; 2024 Mar; 130(6):886-900. PubMed ID: 37960969 [TBL] [Abstract][Full Text] [Related]
4. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Trudel S; Lendvai N; Popat R; Voorhees PM; Reeves B; Libby EN; Richardson PG; Anderson LD; Sutherland HJ; Yong K; Hoos A; Gorczyca MM; Lahiri S; He Z; Austin DJ; Opalinska JB; Cohen AD Lancet Oncol; 2018 Dec; 19(12):1641-1653. PubMed ID: 30442502 [TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1. Miao X; Wu LS; Lin SXW; Xu Y; Chen Y; Iwaki Y; Kobos R; Stephenson T; Kemmerer K; Uhlar CM; Banerjee A; Goldberg JD; Trancucci D; Apte A; Verona R; Pei L; Desai R; Hickey K; Su Y; Ouellet D; Samtani MN; Guo Y; Garfall AL; Krishnan A; Usmani SZ; Zhou H; Girgis S Target Oncol; 2023 Sep; 18(5):667-684. PubMed ID: 37713090 [TBL] [Abstract][Full Text] [Related]
6. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021 [TBL] [Abstract][Full Text] [Related]
7. Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial. Zhou D; Sun Q; Xia J; Gu W; Qian J; Zhuang W; Yan Z; Cheng H; Chen W; Zhu F; Qi K; Li D; Sang W; Zhu L; Ma S; Li H; Zhang H; Qiu T; Yan D; Zhang Y; Peng S; Chang AH; Xu K; Li Z Lancet Haematol; 2024 Oct; 11(10):e751-e760. PubMed ID: 39059405 [TBL] [Abstract][Full Text] [Related]
8. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma. Granger K; Gaffney KJ; Davis JA J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940 [TBL] [Abstract][Full Text] [Related]
9. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma. Martin TG; Mateos MV; Nooka A; Banerjee A; Kobos R; Pei L; Qi M; Verona R; Doyle M; Smit J; Sun W; Trancucci D; Uhlar C; van de Donk NWCJ; Rodriguez C Cancer; 2023 Jul; 129(13):2035-2046. PubMed ID: 36991547 [TBL] [Abstract][Full Text] [Related]
10. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Yan Z; Cao J; Cheng H; Qiao J; Zhang H; Wang Y; Shi M; Lan J; Fei X; Jin L; Jing G; Sang W; Zhu F; Chen W; Wu Q; Yao Y; Wang G; Zhao J; Zheng J; Li Z; Xu K Lancet Haematol; 2019 Oct; 6(10):e521-e529. PubMed ID: 31378662 [TBL] [Abstract][Full Text] [Related]
11. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Bannerji R; Arnason JE; Advani RH; Brown JR; Allan JN; Ansell SM; Barnes JA; O'Brien SM; Chávez JC; Duell J; Rosenwald A; Crombie JL; Ufkin M; Li J; Zhu M; Ambati SR; Chaudhry A; Lowy I; Topp MS Lancet Haematol; 2022 May; 9(5):e327-e339. PubMed ID: 35366963 [TBL] [Abstract][Full Text] [Related]
12. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Mateos MV; Nahi H; Legiec W; Grosicki S; Vorobyev V; Spicka I; Hungria V; Korenkova S; Bahlis N; Flogegard M; Bladé J; Moreau P; Kaiser M; Iida S; Laubach J; Magen H; Cavo M; Hulin C; White D; De Stefano V; Clemens PL; Masterson T; Lantz K; O'Rourke L; Heuck C; Qin X; Parasrampuria DA; Yuan Z; Xu S; Qi M; Usmani SZ Lancet Haematol; 2020 May; 7(5):e370-e380. PubMed ID: 32213342 [TBL] [Abstract][Full Text] [Related]
13. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study. Cortes-Selva D; Perova T; Skerget S; Vishwamitra D; Stein S; Boominathan R; Lau O; Calara-Nielsen K; Davis C; Patel J; Banerjee A; Stephenson T; Uhlar C; Kobos R; Goldberg J; Pei L; Trancucci D; Girgis S; Wang Lin SX; Wu LS; Moreau P; Usmani SZ; Bahlis NJ; van de Donk NWCJ; Verona RI Blood; 2024 Aug; 144(6):615-628. PubMed ID: 38657201 [TBL] [Abstract][Full Text] [Related]
14. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. Chari A; Minnema MC; Berdeja JG; Oriol A; van de Donk NWCJ; Rodríguez-Otero P; Askari E; Mateos MV; Costa LJ; Caers J; Verona R; Girgis S; Yang S; Goldsmith RB; Yao X; Pillarisetti K; Hilder BW; Russell J; Goldberg JD; Krishnan A N Engl J Med; 2022 Dec; 387(24):2232-2244. PubMed ID: 36507686 [TBL] [Abstract][Full Text] [Related]
15. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Zhang M; Wei G; Zhou L; Zhou J; Chen S; Zhang W; Wang D; Luo X; Cui J; Huang S; Fu S; Zhou X; Tang Y; Ding X; Kuang J; He XP; Hu Y; Huang H Lancet Haematol; 2023 Feb; 10(2):e107-e116. PubMed ID: 36725117 [TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554 [TBL] [Abstract][Full Text] [Related]
17. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. Richardson PG; Bringhen S; Voorhees P; Plesner T; Mellqvist UH; Reeves B; Paba-Prada C; Zubair H; Byrne C; Chauhan D; Anderson K; Nordström E; Harmenberg J; Palumbo A; Sonneveld P Lancet Haematol; 2020 May; 7(5):e395-e407. PubMed ID: 32213344 [TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience. Dima D; Davis JA; Ahmed N; Jia X; Sannareddy A; Shaikh H; Shune L; Kaur G; Khouri J; Afrough A; Strouse C; Lochner J; Mahmoudjafari Z; Raza S; Valent J; Anderson LD; Anwer F; Abdallah AO; Hashmi H Transplant Cell Ther; 2024 Mar; 30(3):308.e1-308.e13. PubMed ID: 38151105 [TBL] [Abstract][Full Text] [Related]
19. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Pillarisetti K; Powers G; Luistro L; Babich A; Baldwin E; Li Y; Zhang X; Mendonça M; Majewski N; Nanjunda R; Chin D; Packman K; Elsayed Y; Attar R; Gaudet F Blood Adv; 2020 Sep; 4(18):4538-4549. PubMed ID: 32956453 [TBL] [Abstract][Full Text] [Related]
20. Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma. Girgis S; Lin SXW; Pillarisetti K; Banerjee A; Stephenson T; Ma X; Shetty S; Yang TY; Hilder BW; Jiao Q; Hanna B; Adams HC; Sun YN; Sharma A; Smit J; Infante JR; Goldberg JD; Elsayed Y Target Oncol; 2022 Jul; 17(4):433-439. PubMed ID: 35749004 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]